GSK0660 (Standard)
GSK0660 (Standard) is the analytical standard of GSK0660. This product is intended for research and analytical applications. GSK0660 is a potent PPARβ antagonist with an IC50 of 155 nM.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté : 98%
- CAS No.: 1014691-61-2
- Formule: C19H18N2O5S2
- Masse moléculaire:418.49
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Product Information
-
Chemical Information
- Pureté et documentation
-
Help & FAQs
-
HY-12377
GSK0660PPAR Antagonist -
HY-15577
GSK3787PPARδ Antagonist -
HY-16578
GW9662PPARγ Antagonist -
HY-13202
T0070907PPARγ Antagonist -
HY-15372
GW6471PPARα Antagonist -
HY-13956
PioglitazonePPARγ Agonist -
HY-16995
Pirinixic acidPPAR Agonist -
HY-17356
Fenofibrate -
HY-B0287
ClofibratePPAR Agonist -
HY-17386
RosiglitazonePPARγ Agonist -
HY-B0664
CiprofibratePeroxisome Proliferator -
HY-13861
GW7647PPAR Agonist
Product Information
Information
Application
The compound is the grade of analytical standard, which is the reference standard supplied assay. It is commonly used in qualitative, quantitative and methodological research experiments in HPLC, GC and MS.
Chemical Information
-
CAS No. 1014691-61-2
-
Masse moléculaire 418.49
-
Formule C19H18N2O5S2
-
SMILES
O=C(C1=C(S(=O)(NC2=CC=C(NC3=CC=CC=C3)C=C2OC)=O)C=CS1)OC
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
Références
[1]. Shearer BG, et al. Identification and characterization of a selective peroxisome proliferator-activated receptor beta/delta (NR1C2) antagonist. Mol Endocrinol. 2008 Feb;22(2):523-9. Epub 2007 Nov 1. [Content Brief]
[2]. Zhong X, et al. Bezafibrate enhances proliferation and differentiation of osteoblastic MC3T3-E1 cells via AMPK and eNOS activation. Acta Pharmacol Sin. 2011 May;32(5):591-600. [Content Brief]
[3]. Lee WJ, et al. Activation of PPARδ attenuates neurotoxicity by inhibiting lipopolysaccharide-triggered glutamate release in BV-2 microglial cells. J Cell Biochem. 2018 Feb 1. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
GSK0660 (Standard) Related Classifications
HY-12377R Related Classifications
Powered by Bioz